MK-677 Dosage Protocol: Half-Life, Timing & Cycle Length

MK-677 (ibutamoren mesylate) stands out among growth hormone secretagogues because it is orally bioavailable and has a long half-life of approximately 24 hours. This makes dosing protocol design straightforward compared to injectable GH peptides — but getting the timing, dose, and cycle length right still matters for meaningful research outcomes. For injectable peptides in your protocol, use our free peptide dosage calculator to handle reconstitution math.

Half-Life & Pharmacokinetics

MK-677 has an elimination half-life of approximately 24 hours, which supports once-daily dosing in research protocols. After oral administration, peak plasma concentrations are typically reached within 1–2 hours. The compound’s long half-life means steady-state concentrations are achieved within 4–5 days of consistent daily dosing.

Key pharmacokinetic points:

• Tmax: 1–2 hours post-oral dose
• t½: ~24 hours (supports once-daily dosing)
• Steady state: Reached in approximately 5 days
• GH pulsatility: Maintained — unlike exogenous GH, MK-677 preserves natural pulsatile GH release patterns

Dosage Ranges in Published Research

Clinical studies have tested MK-677 across several dose ranges:

• 10 mg/day: Lowest commonly studied dose. The Murphy et al. (1998) study showed significant increases in GH and IGF-1 at this level in elderly subjects over 2 weeks.
• 25 mg/day: The most frequently studied dose in clinical trials. Nass et al. (2008) used 25 mg daily for 12 months in older adults, showing sustained IGF-1 elevation and increased fat-free mass.
• 50 mg/day: Studied less frequently. Higher doses showed diminishing returns for GH elevation with more pronounced side effects including increased appetite and water retention.

Timing Considerations

Because MK-677 can cause drowsiness and increased appetite, dosing time matters in practical research protocols:

• Evening dosing: Preferred by many researchers to align the GH pulse with natural nocturnal GH secretion and to sleep through appetite-stimulating effects
• Morning dosing: Some protocols use morning dosing when appetite stimulation is not a concern or when monitoring daytime GH/IGF-1 levels
• With or without food: MK-677 can be taken with or without food; absorption is not significantly affected by meal timing

Cycle Length & Long-Term Use

MK-677 is unique among GH secretagogues in that long-term use has been studied in clinical settings. The Nass et al. study ran for a full 12 months, and earlier studies by Chapman et al. covered 2-month periods. Key observations on cycle length:

• Short cycles (4–8 weeks): GH and IGF-1 elevation is rapid and sustained throughout
• Medium cycles (3–6 months): IGF-1 levels remain elevated; some desensitization of GH response may occur but is debated in literature
• Extended use (6–12 months): The Nass study showed IGF-1 remained elevated at 12 months, though GH response modestly decreased over time

Side Effects at Different Doses

Side effect profiles in published trials are dose-dependent:

• Appetite increase: The most consistent effect, driven by MK-677’s ghrelin-mimetic activity. More pronounced at 25–50 mg
• Water retention/edema: Mild to moderate, typically self-resolving within 2–3 weeks
• Fasting glucose: Some studies showed modest increases in fasting blood glucose; the Nass study noted this at 25 mg in elderly subjects
• Lethargy: Commonly reported in the first 1–2 weeks, particularly with evening dosing

Comparison with Injectable GH Peptides

Unlike GHRP-2, GHRP-6, or CJC-1295 — which require subcutaneous injection and precise reconstitution — MK-677 is taken orally as a capsule or liquid solution. This eliminates the need for bacteriostatic water, insulin syringes, and reconstitution calculations. However, researchers combining MK-677 with injectable peptides should use our peptide calculator for accurate reconstitution of the injectable components.